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Spectrum of metastatic and non-metastatic skeletal findings 
with dual-phase 18F-fluoroethylcholine PET/CT in patients 
with biochemical relapse of prostate cancer 
 
ABSTRACT 
The aim of this study was to evaluate the spectrum of skeletal findings on dual-phase 18F-
fluoroethylcholine (FECH) PET/CT performed during the work-up of patients referred 
for suspected prostate cancer relapse.  
Methods: Three hundred 18F-FECH PET/CT scans were prospectively evaluated. The 
low-dose CT features of all cases were categorized as isodense, sclerotic, lytic, or mixed 
lytic/sclerotic and SUVmax values were calculated. Findings on 
18F-FECH PET/CT were 
correlated with 99mTc-MDP planar bone scans and serum PSA. 
Results: Patient age range was 50–90 years (median 71) and PSA values, 0.04–372 
ng/mL (Roche Modular method). Seventy-two lesions were detected on 18F-FECH 
PET/CT in 45 patients, including 31 (43%) in the pelvis, 17 (23%) in the spine {cervical 
3, thoracic 8 and lumbar spine 6}, and 10 (13%) in ribs. Evaluation of low-dose CT in 
combination with PET helped to characterize benign findings in 21 (29%) lesions. The 
SUVmax for all except one benign lesion ranged from 0.49 to 2.15. In 51 lesions (71%) 
due to metastatic disease, SUVmax was 0.6–11.6 for those classified as sclerotic on low-
dose CT, 0.7–8.58 for lytic lesions, 1.1–7.65 for isodense lesions, and 1.27–3.53 for 
mixed lytic/sclerotic lesions. Of the 56 18F-FECH avid lesions, 21 lesions showed 
avidity on bone scan  {3 (23%) of the 13 isodense lesions, 14 (40%) of the 35 
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sclerotic lesions, 2 (50%) of the lytic lesions, and 2 (50%) of the mixed 
sclerotic/lytic lesions}. .  
Conclusion: 18F-FECH PET/CT identified bone lesions in 15% of patients with 
suspected prostate cancer relapse. SUVmax in isolation cannot be used to characterize 
these lesions as benign or malignant. Minimal overlap of benign and malignant lesions 
was seen above SUVmax of 2.5.  Low-dose CT of PET/CT is a useful tool to assist 
characterization.  
 
INTRODUCTION 
Biochemical recurrence after radical prostatectomy or radiation therapy has been 
reported in 27%–53% of patients [1] . Radiology and nuclear medicine techniques play 
an important role in the detection of local relapse and lymph node and skeletal metastases. 
Most institutes rely on magnetic resonance imaging (MRI) for this purpose, with 
increasing emphasis on the multiparametric technique. The main advantage of MRI is its 
excellent anatomic resolution. Nevertheless, positron emission tomography/computed 
tomography (PET/CT) offers benefits due to its increasing ability to demonstrate 
functional characteristics thereby facilitating differentiation between benign and 
malignant lesions. PET imaging is based on labeling of small, biologically and clinically 
significant molecules with positron-emitters. A variety of compounds have been used for 
this purpose, e.g., sugar, amino acids, nucleic acids, receptor binding ligands, water, and 
oxygen. Physiological maps of functions or processes relevant to the labeled molecules 
can be created in real time by imaging the temporal distribution of these compounds [2].  
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In the past decade, tremendous work has been done in elucidating the potential role of 
PET biomarkers in supplementing MRI for the detection of metastatic disease, including 
in morphologically normal lymph nodes, the bone marrow, and the skeleton. While 18F-
fluorodeoxyglucose (FDG) is the most common PET/CT tracer worldwide, the results in 
respect of prostate cancer detection are not very good [3]. Consequently, other tracers 
have been investigated for this purpose, and choline has emerged as one of the most 
common non-FDG PET biomarkers for the evaluation of prostate cancer [4] .  
In a meta-analysis [5], it was found that MRI and choline PET/CT were more accurate 
than bone single-photon emission computed tomography (SPECT) and bone scintigraphy 
(BS) for detecting bone metastases in patients with prostate cancer. The sensitivity and 
specificity of MRI on a per-patient basis were 95% and 96%, respectively, while those of 
choline PET/CT were approximately 87% and 97%, respectively. Though choline 
PET/CT had the highest specificity on a per-patient basis, MRI was significantly better 
than choline PET/CT (p<0.05) and BS (p<0.05) for the detection of bone metastases from 
prostate cancer. The area under the curve (AUC) estimate for MRI (0.9870) on a per-
patient basis was also significantly higher than those for choline PET/CT (0.9541, 
p<0.05) and BS (0.8876, p<0.05). On a per-lesion basis, choline PET/CT had a higher 
AUC (0.9494) than bone SPECT (0.9381) and BS (0.7736) .  
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In vitro data have demonstrated greater 18F-fluorocholine than FDG uptake in androgen-
dependent (LNCaP) and androgen-independent (PC-3) prostate cancer cells [6].  A meta-
analysis by Shen G etal demonstrated that on a per patient basis MRI was better than 
choline PET/CT and bone scan. Choline PET/CT was found to have highest diagnostic 
odds ratio compared to bone SPECT and bone scan. 
There are three commonly used choline-based tracers, namely 18F-fluoroethylcholine 
(18F-FECH), 18F-methylcholine, and 11C-choline, which have a similar physiological 
biodistribution [7] . The purpose of the current study was to evaluate the spectrum of 
skeletal findings on 18F-FECH PET/CT in patients undergoing investigation for 
biochemical relapse of prostate cancer.  
MATERIALS AND METHODS 
A total of 300 18F-FECH PET/CT scans were prospectively evaluated for detection of 
skeletal findings in patients with suspected prostate cancer relapse. 18F-FECH was 
provided by Erigal (Erigal Limited, Downs Road, Sutton, Surrey, UK), synthesized as 
described by Hara et al. [8] .  All QC parameters were fulfilled during the commercial 
preparation. Patients were injected with 300–370 MBq of 18F-FECH (effective dose 
12.95 mSv). Whole-body PET/CT images were acquired 60 min after tracer injection. A 
90-min post-injection dedicated view of the pelvis was also obtained. Owing to the rapid 
excretion of 18F-FECH in urine, patients were asked to empty their bladder prior to 
imaging. The CT acquisition parameters included: scout 120 kVp, 10 mA; CT 140 kVp, 
80 mA, 0.8 s, pitch 1.75; CT slices 5 mm (70-cm FOV PET AC), 2.5 mm (50-cm FOV 
Std), 2.5 mm (50-cm FOV Lung). PET acquisition parameters were: 3D attenuation-
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corrected and non-attenuation-corrected images, 20 subsets with iterative reconstructions. 
CT images were used to produce attenuation correction values for PET emission 
reconstruction and fused PET/CT presentation. The images were read by a nuclear 
medicine physician (with 20 years’ experience) and a radionuclide radiologist (with 5 
years’ experience). The low-dose CT features of all cases were categorized into four 
groups (isodense, sclerotic, lytic, and mixed lytic/sclerotic) and maximum standardized 
uptake values (SUVmax) were calculated. Planar bone scan images were acquired after 
intravenous injection of 99mTc-methylene diphosphonate (MDP) and correlation was 
made with 18F-FECH PET/CT for detection of skeletal lesions. 
Benign lesions on PET/CT were those which were situated at sites of previous trauma, 
joints with arthritic changes (loss of disc space, peri-articular sclerosis, sub-articular cyst 
formation, peri-articular osteophytes), intervertebral discs with degenerative changes, 
facial sinuses with features of sinusitis, avascular necrosis, thickened cortex with bone 
expansion and coarse trabecular pattern (Paget’s disease) and ground glass change 
(fibrous dysplasia). Malignant lesions had 18F FECH avidity, intramedullary location and 
associated altered morphology i-e sclerotic, lytic or mixed pattern. The identification of 
these lesions was based on subjective assessment.  
If the lesion is not metabolically active but showed CT abnormality this either 
reflects a non viable lesion or apoptosis. Lesions which are found to be suspicious 
on PET/CT and there is concordance with other imaging modalities are considered 
highly suspicious for metastatic disease For the purpose of this study (in the 
absence of histology) we have relied on the avidity of the lesions on PET 
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component as gold standard. At the same time we have highlighted the weakness 
of the gold standard. This reflects challenges faced by the radiologists and nuclear 
medicine physicians in multidisciplinary team settings.  
RESULTS 
The age range of the 300 patients was 50–90 years (mean 71.3 years) and PSA values 
were 0.04–372 ng/mL (Roche Modular method). A total of 72 lesions were detected on 
18F-FECH PET/CT in 45 patients (15%).  
Anatomically the distribution of lesions was similar to what is seen in cases of metastatic 
prostate cancer. In our study of the 72 lesions, 31 were found in the pelvis, 17 in the spine 
(cervical 3, thoracic 8 and lumbar spine 6), 10 in ribs, 4 in the sternum, 3 in bone marrow, 
3 in the skull, 2 in the scapula, 1 in the clavicle, and 1 in the femur.  
The final interpretation of the lesions as benign or malignant on 18F FECH PET/CT was 
based on overall anatomical appearances of the lesions and avidity (Fig 1a). Benign 
findings (21/72) included bone island (13), avascular necrosis (1), fibrous dysplasia (1), 
Paget’s disease (1), vertebral fractures (2), advanced focal degenerative changes (2), and 
inflammatory changes (maxillary sinus) (1). The SUVmax for vast majority of benign 
lesions ranged from 0.49 to 2.15. Only one case in this case cohort, with fibrous dysplasia, 
had very high SUVmax (10.8).  
The malignant lesions were further subcategorized based on anatomical appearances on 
the low dose CT as isodense, sclerotic, lytic and mixed lytic or sclerotic lesions. A total 
of 51 lesions were considered to be of malignant etiology. The SUVmax values for the 
malignant lesions ranged from 0.6 to 11.6. The lytic lesions had SUVmax in the range of 
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2.36-8.58, sclerotic lesions 0.6-11.6, isodense lesions 2-7.65 and mixed lytic/sclerotic 
lesions as 2.75-3.53. There were three cases of bone marrow uptake; two were attributed 
to metastatic disease and one, to recent treatment of leukemia. Flow chart of SUVmax 
range of different skeletal lesions is demonstrated in Fig 1 (b) 
18F FECH PET/CT data was further analysed based on avidity on PET component,  
detection of osteoblastic lesions on Bone Scan with a view to segregate lesions which are 
avid on one modality and non avid on the other and vice versa. A true matched analysis  
was possible in 59 /72 lesions as cases where Tc99m MDP Bone Scan was not available 
were excluded from the analysis.  A total of 56/59 lesions were found to be avid on 18F 
Choline PET/CT. The SUVmax value 0.6-11.6.  37.5% (21/56 lesions) demonstrated 
osteoblastic activity while 62.5% (35/56 lesions) were non avid on bone scan (Fig 1c). 
The PSA value ranged from 0.04-372. Detailed analysis of the lesions as isodense, 
sclerotic, lytic, or mixed, SUVmax range, bone scan avidity  and PSA values are listed in 
Table 1.   
There were only 3 lesions which were non avid on 18F FECH PET/CT but were avid on 
Tc99m MDP Bone Scan. All of these three were sclerotic lesions, SUVmax range was 
1.06-1.08 and  PSA value was  3.6-240 (Table 2). 
Fig. 2 shows the scatter plot of SUVmax values in relation to lesion characterization as 
benign or malignant. We noted minimal overlap of benign and malignant lesions was 
seen above SUVmax of 2.5.  
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DISCUSSION 
To our knowledge this is the first study to analyze the correlation between lesion-based 
analysis of skeletal findings on low-dose CT, bone scan, and quantification data obtained 
with 18F-FECH PET/CT. It was observed that 29% of the 18F-FECH PET/CT-positive 
lesions had a benign etiology. The study also demonstrates the superiority of 18F-FECH 
PET/CT over bone scan, given that bone scan detected only 37.5% of the 18F-FECH-avid 
lesions.  
The skeleton is the second most frequent site (after lymph nodes) for metastases from 
prostate cancer, and the incidence of skeletal involvement is 65–75% among patients 
with advanced disease [9] . Among the 15% of patients with bone lesions in this study, 
71% of the lesions were due to metastatic disease. The distribution of skeletal lesions 
overlapped with the sites of spread of prostate cancer, and 43% of the lesions were seen 
in the pelvis (31/72 lesions) and 23.6% in the spine (17/72 lesions), with scattered foci of 
uptake in the remainder of the skeleton. The anatomical area covered in bone scan (skull 
vertex to feet) exceeds that covered on 18F-FECH PET/CT (skull vertex to mid thigh). 
Bone scan did not detect any lesion in the lower limbs, which were not covered on 18F- 
FECH PET/CT.  
A total of 23/51 (45%) malignant lesions were noted to be sclerotic and out of these, 
20.83% (15) were avid on 18F-FECH PET/CT.  Isodense but avid lesions fall into the 
category of “discordant lesions” and pose a different diagnostic dilemma. Detection of 
isodense but “neoplastic lesions” is a real challenge faced while reporting oncology 
scans. The majority of these lesions have a Hounsfield unit value very similar to that of 
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the adjacent bone matrix and these lesions are easily missed on diagnostic CT scans even 
when intravenous contrast is administered. Increased avidity of these lesions as detected 
by 18F-FECH PET/CT helps to distinguish them from surrounding bone. Bone metastases 
undergo osteoblastic healing response with treatment. The isodense lesions may become 
sclerotic and these lesions can be easily labelled as progressive disease. In this study 
there were 13 isodense lesions (SUVmax range 1.1–7.65). Interestingly, out of these only 3 
were avid on bone scan (23.1%) while the majority (76.9%) were non-avid. Even on 
retrospective review of this specific cohort of patients we were not able to identify these 
lesions on the low-dose CT component of the PET/CT. Focal 18F-FECH in isodense 
lesions reflects bone marrow infiltration (Fig 5). Caution should be exercised when 
monitoring isodense lesions.  Reduction in choline uptake with sclerosis can distinguish 
osteoblastic healing response from progressive disease [10] . Figures 3–6 show different 
examples from this study. 
There were three osteoblastic lesions on Tc99m MDP Bone Scan, which were non-avid 
on 18F FECH PET/CT. These included old fractures undergoing osteoblastic healing 
response. These were situated at site of sternal fracture (SUVmax 1.7, PSA 3.6), superior 
end plate fracture at T12 vertebra (SUVmax1.06, PSA 9.2) and right 10th rib fracture 
(SUVmax 1.08, SUVmax 240). The patient with rib fracture had close serial follow up. 
This patient was also found to have a fracture of the 8th rib on the same side which was 
only visible on the low dose CT component and non avid on Bone Scan and 18F FECH 
PET/CT. Due to symmetrical nature but very high PSA a differential of fractures and 
metastatic disease was made. These were found to be stable on 3 serial Bone Scans over a 
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period of 2 years and also on 2 serial CT Scans over 12 months. The patient was put on 
hormones with gradual decline of PSA from 240 to 29.79, 13.07 and 9.14.  
Our cohort demonstrated that quantification of 18F-FECH uptake cannot characterise 
skeletal lesions as benign or malignant in patients undergoing investigation for 
biochemical relapse of prostate cancer and furthermore does not correlate with the 
isodense, sclerotic, lytic, or mixed lytic/sclerotic status of the lesions.  
A major limitation of our study is that the bone scan images were planar images and 
lacked SPECT/CT, which can help with lesion characterization. At our institution, 
staging investigations for prostate cancer include planar images as standard of care in the 
vast majority of prostate cancer patients.   
Histopathological correlation was not available in all cases.  Our institute is a tertiary 
referral center to which a heterogeneous group of patients are referred for imaging from a 
variety of hospitals. We relied on the low-dose CT features to characterize the patients 
and correlated findings with available bone scans. This approach is suboptimal, but the 
study demonstrates that not all avid lesions on 18F-FECH PET are due to a metastatic 
disease process.  
CONCLUSION:   
18F-FECH PET/CT identified bone lesions in 15% of the patients with suspected prostate 
cancer relapse; 71% of the lesions were due to bone metastases and 29% due to benign 
etiology.18F-FECH PET/CT demonstrates a range of benign skeletal findings and caution 
should be exercised in labeling choline-avid lesions as metastatic disease. Quantification 
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of 18F-FECH PET/CT with SUVmax cannot be used to characterize lesions as benign or 
malignant. Minimal overlap of benign and malignant lesions was seen above SUVmax of 
2.5. Low-dose CT acquired as part of the PET/CT may help to characterize tracer-avid 
lesions. Conventional 99mTc MDP bone scan detects only 37.5% of lesions detected by 
18F-FECH PET/CT.  
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Table 1 
 
Low dose CT 
features of 18F 
FECH avid 
lesions 
SUVmax 
range 
Bone Scan 
positive 
Bone Scan 
negative 
PSA 
Range 
 
Isodense 
13 
 
1.1-7.65 
 
3 (23.07%) 
 
10 (76.92%) 
 
3.02-153 
 
Sclerotic 
35 
 
 
0.6-11.6 
 
14 (40%) 
 
21 (60%) 
 
 
2.81-372 
 
Lytic 
4 
 
 
0.7-8.58 
 
2 (50%) 
 
2 (50%) 
 
 
1.2-5.89 
 
 
Mixed 
sclerotic/lytic 
4 
 
 
 
1.27-3.53 
 
2 (50%) 
 
2 (50%) 
 
 
 
0.04-7 
TOTAL 
56 
 
0.6-11.6 
21 
(37.5%) 
35 
(62.5%) 
 
0.04-372 
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Table 2 
 
 
Low dose CT Features of 
non avid 18F FECH 
Lesions showing 
osteoblastic activity on 
Bone Scan  
SUVmax range PSA 
 
 
Isodense 
0 
      NA     NA 
 
Sclerotic 
3 
    1.06-1.08   3.6-240 
 
Lytic 
0 
NA NA 
 
Mixed sclerotic/lytic 
0 
NA NA 
TOTAL 
3 
   1.06-1.08   3.6-240 
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Figure 1 (a) Flow chart demonstrating distribution of the case mix in this 
analysis.  
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Fig 1(b) :  
Flow chart of the SUVmax range of different skeletal lesions characterized as 
benign or malignant on the 18F FECH PET/CT. 
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Fig 1(c):  
Osteoblastic lesions and 18F Choline PET/CT. Only 3 lesions demonstrating osteoblastic 
activity were found to be non-avid on 18F Choline PET/CT. All three related to non -
acute fractures (sternum, vertebra, rib).  
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Figure 2-SUVmax values of benign lesions (B) and malignant lesions (M). There is an 
overlap of SUVmax values between benign and malignant lesions. The only outlier in the 
benign category with intense uptake was a case of fibrous dysplasia with SUVmax greater 
than 11. BM, bone marrow uptake. 
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Figure 3a, b- Multiplanar 18F-FECH PET/CT with coronal, axial,  and MIP (maximum 
intensity projection) images showing sclerosis, periosteal thickening, and low-grade 
uptake at the proximal aspect of the right femur. This patient had a previous history of 
osteomyelitis. 
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Figure 4.  a - Coronal (low-dose CT, PET, and PET/CT) and b axial (low-dose CT and 
PET/CT) 18F-FECH images showing an intensely avid area at the left skull base with 
ground glass appearances on low-dose CT. These findings are in keeping with fibrous 
dysplasia.  
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Figure 5: a, b On CT, there is no evidence of sclerotis, lysis, pedicular destruction, or 
pre- or paravertebral soft tissue abnormailty to indicate metastatic disease.  b Axial 
PET/CT and low-dose CT demonstrate an intensely avid lesion at the upper thoracic 
vertebra, which is in keeping with metastatic disease. In addition, there is an isodense 
metastatic deposit involving the left 4th rib. 
 23 
                                      a 
 
 
 b 
 
 
 
 
Figure 6. a -18F-FECH PET/CT (multiplanar) demonstrating a very faintly avid area at 
the right femoral head with cystic appearances.  b The coronal MRI scan demonstrates a 
focal area of low signal involving the right femoral head with loss of height. This patient 
had a previous history of avascular necrosis of the right femoral head.  
 
